Multiple Myelomas News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

CAR T, immunotherapy bring new hope for multiple myeloma patients - EurekAlert (press release)



OncLive
 
CAR T, immunotherapy bring new hope for multiple myeloma patients 
EurekAlert (press release)
PHILADELPHIA - Two investigational immunotherapy approaches, including chimeric antigen receptor (CAR) T cell therapy, have shown encouraging results in the treatment of multiple myeloma patients who had relapsed and were resistant to other therapies ...
'Unheard of' responses to bluebird CAR-T therapy seen in myeloma ... Reuters
BCMA-Directed bb2121 Highly Effective for Myeloma - OncLive OncLive

all 7 news articles » 


Sequencing offers clues to progression toward multiple myeloma - EurekAlert (press release)



Medical Xpress
 
Sequencing offers clues to progression toward multiple myeloma 
EurekAlert (press release)
ATLANTA -- Researchers at Dana-Farber Cancer Institute have carried out the largest genomic analysis of patients with smoldering multiple myeloma (SMM), a precursor to full-blown blood cancer that doesn't show outward symptoms. The next-generation ...
Tracking how multiple myeloma evolves by sequencing DNA in the ... Medical Xpress

all 9 news articles » 


In multiple myeloma, high levels of enzyme ADAR1 are associated with reduced survival - Science Daily



Science Daily
 
In multiple myeloma, high levels of enzyme ADAR1 are associated with reduced survival 
Science Daily
Multiple myeloma is the second most common blood cancer in the United States. Thirty to 50 percent of multiple myeloma patients have extra copies of the gene that encodes the enzyme ADAR1. Using a database of multiple myeloma patient samples and ...

and more » 


Minimum Residual Disease: A Surrogate Marker for Assessing Outcomes in Multiple Myeloma - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Minimum Residual Disease: A Surrogate Marker for Assessing Outcomes in Multiple Myeloma 
Cancer Therapy Advisor
A minimal residual disease (MRD) cutoff of 10-6 may be used as a novel surrogate biomarker for trial evaluation and be a predictor of progression-free survival (PFS) and overall survival (OS) outcomes among patients with multiple myeloma (MM ...

 


Bluebird, Celgene Myeloma Therapy Appears to Improve in Time - Bloomberg



Bluebird, Celgene Myeloma Therapy Appears to Improve in Time 
Bloomberg
It would be possible to fully enroll the study within a few months and have the therapy available in about a year, said Berdeja, the director of myeloma research. There are about 30,000 new cases of multiple myeloma diagnosed each year in the U.S ...

 


Juno strikes 3 deals to advance multiple myeloma combo treatment - FierceBiotech



FierceBiotech
 
Juno strikes 3 deals to advance multiple myeloma combo treatment 
FierceBiotech
The deals, signed with Eli Lilly, OncoTracker and Fred Hutchinson Cancer Research Center, aim to boost the development of a multiple myeloma therapy combining BCMA-directed CAR-T cells in combination with gamma secretase inhibitors (GSIs). The enzyme ...

and more » 


Sanofi Begins Combo Studies on Multiple Myeloma Candidate - Zacks.com



Sanofi Begins Combo Studies on Multiple Myeloma Candidate 
Zacks.com
Sanofi, Inc. (SNY - Free Report) announced the start of two new phase III studies evaluating its investigational biologic, isatuximab in combination with other cancer medicines for the treatment of multiple myeloma, a rare blood cancer. While the first ...

and more » 


Celgene, Bluebird signal quick start to CAR-T trial in multiple myeloma - STAT



STAT
 
Celgene, Bluebird signal quick start to CAR-T trial in multiple myeloma 
STAT
pivotal phase 2 clinical trial designed to help Celgene (CELG 1) and Bluebird Bio (BLUE 2) secure approval for the first CAR-T therapy targeting multiple myeloma will begin enrolling patients next week. A listing 3 for the clinical trial of the CAR-T ...

 


Expert Discusses Novel Treatment Options in Multiple Myeloma - OncLive



OncLive
 
Expert Discusses Novel Treatment Options in Multiple Myeloma 
OncLive
Are there any other ongoing studies in multiple myeloma that are particularly interesting? Now, a lot of studies are looking at the inclusion of stem cell transplant, and the timing of stem cell transplant in patients with multiple myeloma. There are a ...

 


FDA Removes Holds on 2 Nivolumab-Based Multiple Myeloma Clinical Trials - Targeted Oncology



The Pharma Letter
 
FDA Removes Holds on 2 Nivolumab-Based Multiple Myeloma Clinical Trials 
Targeted Oncology
The partial clinical holds placed on the phase I CheckMate-039 and phase II CA204142 trials in October were lifted today by the FDA. Both trials were exploring nivolumab-based regimens in patients with relapsed/refractory multiple myeloma. The partial ...
FDA Lifts Clinical Hold on Nivolumab Combinations for Multiple Myeloma Specialty Pharmacy Times
Bristol-Myers continues multiple myeloma trials after FDA lifts partial holds The Pharma Letter

all 3 news articles »